IceCure Medical (ICCM)
(Real Time Quote from BATS)
$0.73 USD
+0.03 (4.78%)
Updated Jul 23, 2024 10:34 AM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ICCM 0.73 +0.03(4.78%)
Will ICCM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ICCM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ICCM
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
ICCM: What are Zacks experts saying now?
Zacks Private Portfolio Services
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates
Other News for ICCM
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society
IceCure ProSense® Shows Remarkable Cancer Results
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical receives non-compliance notice for continued listing from Nasdaq
IceCure Medical receives noncompliance notification from Nasdaq